Agennix USA Inc.

Other

Gpc Biotech, Inc.

Gpc Biotech Ag

Nicholas Bockovich

Arthur F Kluge

Krishna K Murthi

Chris Oalmann

Zhongguo Wang

Siya Ram

Jianxing Huang

Frank Becker

Jon H Come

The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, untimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.

Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.

Growing community of inventors

Malden, MA, United States of America

Nicholas Bockovich